Drugs / BL-M07D1
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06293898 | Feb 2024 → Dec 2028 expected | biliary tract cancer, breast cancer, cervical cancer, endometrial cancer +6 | SystImmune Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05631964 | Jan 2023 → Dec 2026 expected | digestive system cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05461768 | Aug 2022 → Dec 2026 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06114511 | Apr 2024 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06131450 | Feb 2024 → Dec 2026 expected | female reproductive organ cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06031584 | Jan 2024 → Dec 2026 expected | — | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07678957 | Aug 2026 → Dec 2028 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07264816 | Feb 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06423885 | Dec 2024 → Oct 2026 expected | gastroesophageal adenocarcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06445400 | Jun 2024 → Dec 2026 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06891833 | Jun 2025 → Dec 2028 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07545460 | Jul 2026 → Dec 2028 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07606599 | May 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07518173 | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07178795 | Sep 2025 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07152405 | Sep 2025 → Jun 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06830889 | Jun 2025 → Oct 2031 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06957886 | May 2025 → May 2027 expected | breast carcinoma by gene expression profile | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06316531 | May 2024 → May 2026 overdue | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M07D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05461768 ↗ |
| Route | Intravenous | “Administration by intravenous infusion” NCT05461768 ↗ |